Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Cogstate reports strong growth for FY 2026, revenue well below expectations

Cogstate recorded revenue growth of 15% to AUD 60.9m in fiscal 2026, improved profitability and a 55% increase in active clinical studies to 171. However, the most recently reported quarterly revenues of $21.85m were 49.8% below the Wall Street estimate of $43.51m, weighing on the stock. New contracts rose 116% to AUD 89m and contracted future revenue stands at nearly AUD 120m, providing visibility for 2027. Management plans automation investments in AI, expects an EBITDA margin of around 30% for 2027, and announced a higher dividend plus an open buyback program. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, COGSTATE LTD. Aktie has already paid €0.0249 in dividends. The last payout was in September.

Financials

In the last quarter, COGSTATE LTD. Aktie had revenue of €28.33m and net profit of €6.36m

(EUR)	June 2026	YoY
Revenue	28.33m	-
Gross profit	10.95m	-
Net profit	6.36m	-
EBITDA	8.59m	-

Fundamentals

Metric	Value
Market capitalization	€373.01m
Number of shares	172.13m
52-week high/low	€2.48 - €1.09
Dividend yield	1.13%
Dividends TTM	€0.0249
Beta	0.19
P/E ratio	35.24
PEG ratio	2.23
P/B ratio	7.18
P/S ratio	7.20

Company profile

Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.